about
What makes psoriatic and rheumatoid arthritis so different?C5orf30 is a negative regulator of tissue damage in rheumatoid arthritisComparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.Production of angiotensin converting enzyme by rheumatoid synovial membrane.Increased prevalence of symptomatic macrovascular disease in systemic sclerosisRandomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medicationToll-like receptor 2 induced angiogenesis and invasion is mediated through the Tie2 signalling pathway in rheumatoid arthritis.Detection of Mycobacterium tuberculosis group organisms in human and mouse joint tissue by reverse transcriptase PCR: prevalence in diseased synovial tissue suggests lack of specific association with rheumatoid arthritisDifferential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease.Pathways of cell activation in spondyloarthropathies.Management of spondyloarthropathy: new pharmacological treatment options.Psoriatic arthritis--pathogenesis and epidemiology.Assessment of disease activity.Overexpression of transcripts containing LINE-1 in the synovia of patients with rheumatoid arthritis.Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis.Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergyImmunopathology of psoriasis and psoriatic arthritisIs remission a more realistic goal in psoriatic arthritis?Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go?Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis.Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysisMigrating Polyarthritis as a Feature of Occult Malignancy: 2 Case Reports and a Review of the Literature.Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitorsInhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting.Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohortBiomarkers in systemic sclerosis.Psoriatic arthritis management update - biotherapeutic options.Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis.How early should psoriatic arthritis be treated with a TNF-blocker?A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service.Macrophages in synovial inflammation.Psoriatic arthritis: recent progress in pathophysiology and drug development.The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.Biomarkers for rheumatoid and psoriatic arthritis.Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements.CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression.Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis.Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
P50
Q26778261-A57F29B2-9FB0-4B26-9B17-1C27B3B2E186Q28590707-4CAF0695-E57E-4B32-B5FD-C2C0D82FFA7EQ33390265-6870D2F9-C3DF-439C-878B-563A7E3E197EQ33564523-37FDA604-600F-4435-9ECF-E462B045E16BQ33578449-3AB32F36-96DF-43C7-B8B2-95F420D7A7EBQ33792588-C4390B96-9E37-4F7E-9B4D-6860136DBED4Q33999774-2FC77037-F9A7-4BDF-ADCA-E75B8C8ADF5EQ34006506-E83236D3-5B52-4479-A3A7-054EB1B1D17BQ34079261-167A2BF9-2669-4EAB-9994-5FB9A75F4152Q34374521-1421AFD6-E531-4EBA-B6F8-FE2B3BFAAC2DQ34978711-0076260C-01A2-4962-8D31-E7909CC87D13Q35015337-30FF36E1-ABC5-49BE-ADD2-3EE6E47FD246Q35188039-B1CF146E-49BB-4B83-980A-618FEF0B59E0Q35552816-DA5B8BAD-96C7-4178-8515-F671FD1DFD7EQ35830873-EA45A2F2-85B2-43F3-BC45-AE003F8BC6CEQ36011107-03A03424-C6B5-41EB-8FD2-EACA89A44F9CQ36040037-3D9A7225-7DA9-4D50-A0A6-E23C88E351D7Q36059579-759FBD6A-A33B-4B0A-A783-E322183F0E49Q36173601-E9455A51-F99A-44B8-A3C3-C65D9C95D198Q36208106-EDE3A322-BB24-4863-98CD-B99E71EB7B07Q36220823-2111BE6B-B8B3-44D2-911A-F96C6B26A0A5Q36237324-DAF82607-9F62-4B73-8C75-A0B7379729BFQ36475599-55683726-08C1-424B-A7FB-3DBAF59952FCQ36596158-42D18092-7D08-477A-9D09-9040D1613ACAQ36876705-BBD7C95C-75C5-44A0-8C40-009E0EFFCAEDQ37265106-B1C64DD0-0C55-4107-B9D3-8FEA9A856AF5Q37265824-5B7C5A00-D59B-4CB1-AFAC-19913991C219Q37574759-FBCF0DFB-F751-4BA8-AF62-D1417559D720Q37689754-AEDEBEBD-F919-4DA9-8329-BD0488104B99Q37753594-DE78491B-89CF-4AE0-9F3B-C2ECDAA64801Q37762433-40A9BC1E-BC6E-4CF9-ABC6-2C8CA25115ACQ38001590-A63FC1B3-B93D-4814-86F8-5E04AAD0B344Q38008340-7B5A4227-1F45-4954-BE33-ACEB5A3DC8B2Q38194559-21DF9462-CECF-4491-A620-BFE03B604D3BQ38391791-987EE782-DCF3-4829-91A4-E07637E842F1Q38454424-25C00055-8E79-4009-9BAA-BFD55D3D42C9Q38512329-F74B59CF-1319-4C70-915E-3FE417A0AFD0Q38813486-7F7AC206-8534-4031-A03E-16B43D05F514Q38844323-FFA4C1A4-E286-4E1A-8EA1-BF5548258311Q38966586-064147D2-9880-462C-94BC-4A5E45F1DAC0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Douglas J Veale
@ast
Douglas J Veale
@en
Douglas J Veale
@es
Douglas J Veale
@nl
Douglas J Veale
@sl
type
label
Douglas J Veale
@ast
Douglas J Veale
@en
Douglas J Veale
@es
Douglas J Veale
@nl
Douglas J Veale
@sl
prefLabel
Douglas J Veale
@ast
Douglas J Veale
@en
Douglas J Veale
@es
Douglas J Veale
@nl
Douglas J Veale
@sl
P106
P21
P31
P496
0000-0003-2802-4971